The most commonly reported adverse events (observed in greater than 5% of clinical trial participants) were nausea, diarrhea, vomiting, constipation, abdominal pain, dyspepsia, injection-site reactions, fatigue, hypersensitivity reactions, eructation, hair loss and gastroesophageal reflux disease
A collaborative approach between patient and healthcare team ensures optimal diabetes management whilst addressing any psychological concerns that arise during treatment
Providers can review individual kidney function, stomach ulcer risk factors, and concurrent medications to establish personalized safety guidelines
Glucagon-like peptide-1 agonists are contraindicated for patients with a personal or family history of medullary thyroid cancer or multiple endocrine neoplasia syndrome type 2 and who are receiving treatment with dipeptidyl-peptidase-4 inhibitors
a 0.25 mg example is then 0.25 / 2.5 = 0.1 mL, which is 10 units on a U-100 syringe
Start Saving on Wegovy
